Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA - XML Representation

Raw xml | Download


<EvidenceVariable xmlns="http://hl7.org/fhir">
  <id value="236950"/>
  <meta>
    <versionId value="63"/>
    <lastUpdated value="2024-10-03T13:11:20.368Z"/>
    <profile
             value="http://hl7.org/fhir/uv/ebm/StructureDefinition/group-assignment"/>
  </meta>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: EvidenceVariable 236950</b></p><a name="236950"> </a><a name="hc236950"> </a><a name="236950-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">version: 63; Last updated: 2024-10-03 13:11:20+0000</p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-group-assignment.html">GroupAssignment</a></p></div><p><b>url</b>: <a href="https://fevir.net/resources/EvidenceVariable/236950">https://fevir.net/resources/EvidenceVariable/236950</a></p><p><b>identifier</b>: FEvIR Object Identifier/236950, FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-group-assignment-85394-85798</p><p><b>name</b>: GroupAssignment_SGLT2_inhibitors_vs_GLP_1_RA</p><p><b>title</b>: GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA</p><p><b>status</b>: Active</p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href="mailto:support@computablepublishing.com">support@computablepublishing.com</a></p><p><b>description</b>: </p><div><p>This EvidenceVariable Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>
</div><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>
</div><p><b>author</b>: Computable Publishing®: MAGIC-to-FEvIR Converter: </p><h3>RelatedArtifacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>ResourceReference</b></td></tr><tr><td style="display: none">*</td><td>Part Of</td><td>MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)</td></tr></table><h3>Definitions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Concept</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 defined-in-handling-and-category}">Defined in handling and category elements</span></td></tr></table><p><b>handling</b>: dichotomous variable</p><blockquote><p><b>category</b></p><p><b>name</b>: SGLT2 inhibitors</p><p><b>value</b>: <a href="Group-236769.html">Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors</a></p></blockquote><blockquote><p><b>category</b></p><p><b>name</b>: GLP-1 RA</p><p><b>value</b>: <a href="Group-236776.html">Glucagon-Like Peptide-1 (GLP-1) receptor agonists</a></p></blockquote></div>
  </text>
  <url value="https://fevir.net/resources/EvidenceVariable/236950"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="https://fevir.net"/>
    <value value="236950"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <identifier>
    <type>
      <text value="FEvIR Linking Identifier"/>
    </type>
    <system value="https://fevir.net/FLI"/>
    <value value="MAGIC-5288-j1Wqrn-group-assignment-85394-85798"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <name value="GroupAssignment_SGLT2_inhibitors_vs_GLP_1_RA"/>
  <title value="GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA"/>
  <status value="active"/>
  <publisher value="Computable Publishing LLC"/>
  <contact>
    <telecom>
      <system value="email"/>
      <value value="support@computablepublishing.com"/>
    </telecom>
  </contact>
  <description
               value="This EvidenceVariable Resource is referenced in an example for the EBMonFHIR Implementation Guide."/>
  <copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
  <author>
    <name value="Computable Publishing®: MAGIC-to-FEvIR Converter"/>
  </author>
  <relatedArtifact>
    <type value="part-of"/>
    <resourceReference>
      <type value="Composition"/>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="MAGIC-5288-j1Wqrn-conversion-report"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <display
               value="MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"/>
    </resourceReference>
  </relatedArtifact>
  <definition>
    <concept>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="defined-in-handling-and-category"/>
        <display value="Defined in handling and category elements"/>
      </coding>
    </concept>
  </definition>
  <handling value="dichotomous"/>
  <category>
    <name value="SGLT2 inhibitors"/>
    <valueReference>🔗 
      <reference value="Group/236769"/>
      <type value="Group"/>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="MAGIC-5288-j1Wqrn-intervention-85394-I-85798"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <display value="Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors"/>
    </valueReference>
  </category>
  <category>
    <name value="GLP-1 RA"/>
    <valueReference>🔗 
      <reference value="Group/236776"/>
      <type value="Group"/>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="MAGIC-5288-j1Wqrn-comparator-85394-C-85798"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <display value="Glucagon-Like Peptide-1 (GLP-1) receptor agonists"/>
    </valueReference>
  </category>
</EvidenceVariable>